Sept 22 (Reuters) - SciClone Pharmaceuticals Inc said its drug candidate for the treatment of chronic Hepatitis C virus (HCV) showed antiviral activity in a mid-stage trial for patients who had relapsed after responding to prior treatments. The drug, SCV-07, was tested in a trial that evaluated its effect on Hepatitis C viral load, a measure of the severity of a viral infection, and other measures of immune response.
